- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02518620
An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis
A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX-0061
Study Overview
Detailed Description
Eligible subjects received one of the following treatments during the preceding Phase IIb studies ALX0061-C201 and ALX0061-C202:
Study ALX0061-C201:
- Placebo (+ methotrexate [MTX]), or
- ALX-0061 75 mg every 4 weeks (q4w) (+ MTX), or
- ALX-0061 150 mg q4w (+ MTX), or
- ALX-0061 150 mg every 2 weeks (q2w) (+ MTX), or
- ALX-0061 225 mg q2w (+ MTX), for 24 weeks
Study ALX0061-C202:
- ALX-0061 150 mg q4w, or
- ALX-0061 150 mg q2w, or
- ALX-0061 225 mg q2w, for 12 weeks
At the Week 24 (ALX0061-C201) or Week 12 (ALX0061-C202) visit of the previous study, informed consent was obtained from all subjects who were deemed potentially eligible for the OLE study, according to the inclusion and exclusion criteria. This was marked as the Week 0 visit of the C203 study. Of note, the Baseline time point in the analyses of this study was defined the Baseline value of the parent study.
In this OLE study, eligible subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and every 2 weeks thereafter, up to and including Week 102. Eligible subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
Maintenance of the response (i.e., at least 20% improvement in both SJC and TJC compared to Baseline of the preceding study) was reassessed at the study visits at Weeks 12, 24, 36, 48, 60, 72, 84, and 96. Subjects who failed to maintain response and met the Efficacy Discontinuation Criteria were discontinued from this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium
- Investigator Site 1
-
Brussels, Belgium
- Investigator Site 2
-
Ghent, Belgium
- Investigator site
-
Liège, Belgium
- Investigator site
-
-
-
-
-
Burgas, Bulgaria
- Investigator site
-
Pleven, Bulgaria
- Investigator site
-
Plovdiv, Bulgaria
- Investigator site
-
Ruse, Bulgaria
- Investigator site
-
Sofia, Bulgaria
- Investigator Site 1
-
Sofia, Bulgaria
- Investigator Site 2
-
-
-
-
-
Tbilisi, Georgia
- Investigator Site 1
-
Tbilisi, Georgia
- Investigator Site 2
-
Tbilisi, Georgia
- Investigator Site 3
-
Tbilisi, Georgia
- Investigator Site 4
-
Tbilisi, Georgia
- Investigator Site 5
-
-
-
-
-
Hamburg, Germany
- Investigator site
-
-
-
-
-
Baja, Hungary
- Investigator site
-
Balatonfüred, Hungary
- Investigator site
-
Bekescsaba, Hungary
- Investigator site
-
Gyula, Hungary
- Investigator site
-
Szikszó, Hungary
- Investigator site
-
Szombathely, Hungary
- Investigator site
-
Székesfehérvar, Hungary
- Investigator site
-
Veszprém, Hungary
- Investigator site
-
-
-
-
-
Culiacán, Mexico
- Investigator site
-
León, Mexico
- Investigator site
-
Mexico City, Mexico
- Investigator Site 1
-
Mexico City, Mexico
- Investigator Site 2
-
Monclova, Mexico
- Investigator site
-
Monterrey, Mexico
- Investigator Site 1
-
Monterrey, Mexico
- Investigator Site 2
-
Mérida, Mexico
- Investigator site
-
-
-
-
-
Chisinau, Moldova, Republic of
- Investigator Site 1
-
Chisinau, Moldova, Republic of
- Investigator Site 2
-
-
-
-
-
Skopje, North Macedonia
- Investigator Site 1
-
Skopje, North Macedonia
- Investigator Site 2
-
-
-
-
-
Bydgoszcz, Poland
- Investigator site
-
Elbląg, Poland
- Investigator Site 1
-
Elbląg, Poland
- Investigator Site 2
-
Gdynia, Poland
- Investigator site
-
Grodzisk, Poland
- Investigator site
-
Katowice, Poland
- Investigator site
-
Lublin, Poland
- Investigator site
-
Poznan, Poland
- Investigator site
-
Sochaczew, Poland
- Investigator site
-
Torun, Poland
- Investigator site
-
Warszawa, Poland
- Investigator Site 1
-
Warszawa, Poland
- Investigator Site 2
-
-
-
-
-
Galați, Romania
- Investigator site
-
Oradea, Romania
- Investigator site
-
-
-
-
-
Belgrade, Serbia
- Investigator Site 1
-
Belgrade, Serbia
- Investigator Site 2
-
Belgrade, Serbia
- Investigator Site 3
-
Niska Banja, Serbia
- Investigator site
-
-
-
-
-
Madrid, Spain
- Investigator site
-
Santander, Spain
- Investigator site
-
Santiago de Compostela, Spain
- Investigator site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must have been eligible for one of the preceding Phase IIb studies with ALX-0061 (study ALX0061-C201 or ALX0061-C202), have been randomized to placebo or one of the ALX-0061 arms (subjects randomized to tocilizumab [TCZ] in study ALX0061-C202 were not eligible), and completed the entire treatment and assessment period of the preceding studies (i.e., 24 weeks for study ALX0061-C201 and 12 weeks for study ALX0061-C202).
- Must have reached at least 20% improvement in SJC and/or TJC (66/68 counts) compared to Week 0 at Week 24 for subjects participating in the preceding Phase IIb ALX0061 C201 study, or at Week 12 for subjects participating in the preceding Phase IIb ALX0061-C202 study
- Female subjects of childbearing potential (excluding postmenopausal women, sterilized, ovariectomized, and hysterectomized women) must agree to use 2 generally accepted adequate contraceptive methods of which 1 is a barrier method (e.g., hormonal contraception stabilized for at least 1 month [oral, patch, depot, injectable, vaginal ring] in combination with condom by partner) or should agree upon continuous abstinence from heterosexual contact from screening/baseline until at least 6 months after last dosing. Male subjects must use condoms for the duration of the study and for at least 6 months after last administration of study drug.
- Ability to comprehend and willingness to sign the informed consent form (ICF).
- An understanding of and ability and willingness to adhere to the study visit schedule and other protocol requirements.
Exclusion Criteria:
- Received TCZ during the previous Study ALX0061-C202.
- Received any prohibited treatment during the previous Phase IIb studies (ALX0061-C201 or ALX0061-C202.
- Diagnosis of or suspicion of a serious infection (requiring parental antibiotics and/or hospitalization) or tuberculosis during the preceding study.
- Diagnosis of malignancy or demyelinating disease during the preceding study.
- Any active or recurrent viral infection that made the subject unsuitable for the study based on the Investigator's clinical assessment, including recurrent/disseminated herpes zoster.
- Diagnosis of congestive heart failure class III or IV (as defined by the New York Heart Association), unstable angina pectoris, myocardial infarction, and/or cerebrovascular accident during the preceding study.
Abnormality in laboratory test results observed at the Week 22 visit for subjects participating in the preceding Phase IIb ALX0061-C201 study, or observed at the Week 10 visit for subjects participating in the preceding Phase IIb ALX0061-C202 study:
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels ≥ 2 times the upper limit of normal (ULN).
- Hemoglobin levels ≤ 85 g/L (8.5 g/dL).
- Platelet count ≤ 75 x 109/L (75,000 cells/mm³).
- Absolute neutrophil count < 1.5 x 109/L.
- Serum creatinine levels ≥ 1.5 mg/dL (133 μmol/L).
- Any other clinically significant abnormal laboratory result as evaluated by the Investigator.
- If no laboratory test results of the Week 22 Visit (for subjects participating in the preceding ALX0061-C201 study) or the Week 10 Visit (for subjects participating in the preceding ALX0061-C202 study) were available, then laboratory values of tests performed between Week 22 and 24 (for study ALX0061-C201) or Week 10 and 12 (for study ALX0061-C202) were taken into account for the exclusion criteria a to e listed above.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ALX-0061 150 mg q2w (+ MTX)
|
Subjects received ALX-0061 150 mg s.c.
injections, beginning at Week 0 and q2w thereafter, up to and including Week 102.
Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and Percentage of Subjects With American College of Rheumatology (ACR) 20 Response.
Time Frame: At Weeks 0, 12, 48, and 104
|
ACR 20 response is defined as:
ACR20 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported. |
At Weeks 0, 12, 48, and 104
|
Number and Percentage of Subjects With ACR50 Response.
Time Frame: At Weeks 0, 12, 48, and 104
|
ACR50 response is defined as:
ACR50 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported. |
At Weeks 0, 12, 48, and 104
|
Number and Percentage of Subjects With ACR70 Response.
Time Frame: At Weeks 0, 12, 48, and 104
|
ACR70 response is defined as:
ACR70 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported. |
At Weeks 0, 12, 48, and 104
|
ACR-N Index of Improvement
Time Frame: At Weeks 0, 12, 48, and 104
|
The ACR-N Index of Improvement is defined as the minimum of the following 3 criteria:
ACR-N Index of Improvement was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported. |
At Weeks 0, 12, 48, and 104
|
Number and Percentage of Subjects in Remission or With Low, Moderate or High Disease Activity Based on Disease Activity Score Using 28 Joint Counts (DAS28) Using Estimated Sedimentation Rate (ESR)
Time Frame: At Weeks 0, 12, 48, and 104
|
DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Disease activity based on DAS28(ESR) was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported. |
At Weeks 0, 12, 48, and 104
|
Number and Percentage of Subjects With DAS28 Using C-reactive Protein (CRP) < 2.6, Low, Moderate or High Disease Activity Based on DAS28(CRP)
Time Frame: At Weeks 0, 12, 48, and 104
|
DAS28(CRP) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.36 × ln[CRP+1]) + (0.014 × VASPA) + 0.96
Disease activity based on DAS28(CRP) was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported. |
At Weeks 0, 12, 48, and 104
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Monitor, Ablynx NV
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALX0061-C203
- 2014-003034-42 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on ALX-0061
-
AblynxCompleted
-
AblynxCompletedRheumatoid ArthritisPoland, Hungary, Czechia
-
AblynxCompletedLupus Erythematosus, SystemicUnited States, Hungary, Spain, Philippines, Poland, Serbia, Argentina, Chile, Czechia, Germany, Korea, Republic of, Mexico, Peru, Portugal, Russian Federation, Taiwan, Ukraine
-
AblynxCompletedRheumatoid ArthritisCzechia, Bulgaria, Germany, Mexico, Poland, Romania, Serbia, Spain, Hungary, United States, Belgium, Georgia, Moldova, Republic of, North Macedonia
-
Ralexar Therapeutics, Inc.CompletedAtopic Dermatitis | Eczema, AtopicUnited States
-
Ablynx, a Sanofi companyCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, Switzerland, Turkey, United Kingdom
-
Ralexar Therapeutics, Inc.Unknown
-
Allyx TherapeuticsMichael J. Fox Foundation for Parkinson's ResearchRecruitingParkinson DiseaseUnited States
-
AblynxTerminated
-
AblynxCompletedRespiratory Syncytial Virus Lower Respiratory Tract InfectionBelgium, Hungary, Israel, Spain, Estonia, Philippines, Thailand, Bulgaria, Poland, Germany, Chile, Colombia, Croatia, Czechia, Latvia, Malaysia, Slovakia